Biosimilar DMARD in rheumatology: A general perspective with focus on India

Indian Journal of Rheumatology

Volumn 7, Issue 2, 2012, Pages 89-96

  Chopra, Arvind ^a   Shankar, Subramanian ^b  

^a Center for Rheumatic Diseases   (India)

^b ARMED FORCES MEDICAL COLLEGE   (India)

Author keywords

Biologic; Biosimilar; DMARD; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; AVENT; AVG01; BIOSIMILAR AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; PARATHYROID HORMONE[1-34]; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXICAN; RITUXIMAB; TOCILIZUMAB; UNCLASSIFIED DRUG;

BIOEQUIVALENCE; DISEASE ACTIVITY; DISEASE COURSE; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MECHANISM; DRUG POTENCY; DRUG PURITY; DRUG QUALITY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GLYCOSYLATION; GOOD MANUFACTURING PRACTICE; HUMAN; IMMUNOGENICITY; INDIA; PATIENT ATTITUDE; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REMISSION; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; TREATMENT INDICATION;

EID: 84991839837     PISSN: 09733698     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.injr.2012.04.005     Document Type: Review

References (21)

1. M. McCamish, and G. Woollett The state of the art in the development of biosimilars Clin Pharmacol Ther 91 3 2012 Mar 405 417
2. V. Joshi, and A. Chopra Is there an urban rural divide? Population surveys of rheumatic musculoskeletal disorders in the Pune region of India using the COPCORD Bhigwan model J Rheum 36 2009 3
3. S. Kozlowski, J. Woodcock, K. Midthun, and R. Sherman Developing the Nation's biosimilars program N Engl J Med 365 2011 385 388
4. H. Mellstedt, D. Niederwieser, and H. Ludwig The challenge of biosimilars Ann Oncol 19 2008 411 419 (Pubitemid 351325660)
5. S.D. Roger, and A. Mikhail Biosimilars: opportunity or cause for concern? J Pharm Pharmaceut Sci 10 3 2007 405 410 (Pubitemid 350065566)
6. J. Kay Biosimilars: a regulatory perspective from America Arthritis Res Ther 13 2011 112
7. Guideline on similar biological medicinal products 2005 European Medicines Agency London http://www.emea.europa.eu/pdfs/human/biosimilar/ 043704en.pdf
8. Draft: guideline on similar biological medicinal products containing monoclonal antibodies 2010 European Medicines Agency London http://www.ema. europa.eu/docs/en-GB/document-library/Scientific-guideline/2010/11/WC500099361. pdf
9. J. Woodcock, J. Griffin, and R. Behrman The FDA's assessment of follow-on protein products: a historical perspective Nat Rev Drug Discov 6 2007 437 442 (Pubitemid 47078655)
10. Biologics price competition and Innovation Act 2009 http://www.fda.gov/ downloads/Drugs/GuidanceComplianceRegulatoryInformation/UCM216146.pdf
11. H. Mellstedt Impications of the development of biosimilars for cancer treatment Future Oncol 6 7 2010 1065 1067
12. H. Schellekens Bioequivalence and the immunogenicity of biopharmaceuticals Nat Rev Drug Discov 1 2002 457 462 (Pubitemid 37361488)
13. R. Mody, V. Goradia, and D. Gupta How similar are Biosimilars in India? A blind comparative study Available from: http://www.pharmafocusasia.com/ research-development/blind-comparative-study.html [accessed 01.06.10]
14. B.A. Liang, and T. Mackey Emerging patient safety issues under health care reform: follow-on biologics and immunogenicity Ther Clin Risk Manage 7 2011 489 493
15. F. Locatelli, and H. Becker Update on Anemia management in Nephrology, including current guidelines on the use of Erythropoiesis-stimulating agents and implications of the Introduction of "Biosimilars" Oncologist 14 suppl 1 2009 16 21
16. P. Minghetti, P. Rocco, L. Vecchio del, and F. Locatelli Biosimilars and regulatory Authorities Nephron Clin Pract 117 2011 c1 c7 10.1159/000319640
17. R. Nellore Regulatory Considerations for biosimilars Perspect Clin Res 1 1 2010 Jan-Mar 11 14
18. Monika Misra Biosimilars: current perspectives and future implications Ind J Pharmacol 44 1 2012 Jan-Feb 12 14 10.4103/0253-7613.91859
19. http://www.biospectrumasia.com/content/151110OTH14603.asp
20. http://biospectrumindia.ciol.com/content/CoverStory/10812056.asp
21. Maity S, Ullanat R, Lahiri S, et al. A non-innovator version of etanercept for treatment of arthritis. Biologicals. 2011 Oct 11: 21996051.